Natco Pharma is doing pretty well today morning opened around 4.5% higher at Rs.880 and then surged to an intraday high at Rs.900, up 9%. Volumes are up almost 3-times.

The market has given it’s a thumbs up after it announced yesterday evening that along with its marketing partner Arrow International Ltd (an affiliate of Teva Pharmaceutical Industries Ltd), has announced the launch of first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 100 mg, 15 mg, and 25 mg strengths in the US market.

The capsules are prescribed in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment.

Natco and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).